Oura announced a $625 million cash agreement to acquire Counsel Health on November 10. The price is subject to adjustments, and closing is expected before year-end, subject to conditions.

The big change

  • The companies already connect wearable insights with Counsel’s medical AI and physicians. Their proposed expansion covers preventive, acute and ongoing care; the acquisition has not yet closed.
  • New connections receive 30 days of medical AI. Doctor access, or AI after the trial, requires the separate $159 annual upgrade. Existing paid subscribers retain their price pending renewal notice.
  • Onboarding requires sharing all listed Oura categories, without individual selection: these include sleep, activity, reproductive information and identifying details. Sending consultation information back to Oura is optional.

From an insight to a clinical conversation

According to the companies, members can add a physician to an AI conversation for diagnosis, prescriptions or referrals when appropriate. The ring is not a medical device, and Counsel is not for emergencies.

For illustration, a member could bring an unusual sleep trend to that conversation. Reviewing a shared history provides context; it does not show that the ring has identified the cause.

Physician involvement does not establish that every AI reply receives individual clinical review.

Current access and consent

Oura Labs currently offers Counsel experimentally in 43 US states. It requires Gen3 or later and active membership. Check the help page’s exclusions before enrolling.

The subscription is not covered by insurance; resulting prescriptions or treatments may be. The free trial should not be read as free physician care.

Either sharing direction can be stopped. Revoking access does not cancel the subscription; deleting Oura information does not erase Counsel’s separate medical record, which it must retain.

Choosing to connect, choosing to share information back, ending a subscription and requesting deletion answer different questions. Review each decision separately rather than assuming that one control reverses every earlier choice.

What would establish useful care?

The World Health Organization’s 2024 guidance summary explains why conversational fluency is not enough to judge medical AI. It identifies false, inaccurate, biased or incomplete statements as risks when people use generated information to make health decisions.

WHO also describes automation bias: patients or clinicians may overlook errors because they rely on an automated system, or delegate difficult choices to it. It recommends well-defined tasks, appropriate accuracy and reliability, and independent assessments when systems are deployed at scale.

This is general guidance, not an evaluation of Counsel. A useful assessment asks what was measured, in which patients, against which alternative and with what harms or failures. Satisfaction with a conversation and an improvement in clinical outcomes answer different questions.

BIG CHANGE has not independently tested the service or verified the companies' clinical claims.